EOLS

Evolus, Inc.

$6.81

-2.44%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Source: Yahoo Finance
AI summary

Price & performance

1M-9.0%
3M+10.0%
YTD+1.1%
1Y-0.2%
52-week range—
Beta1.18
Full chart and returns against a benchmark

Q-Score

54/ 100

Quality against peers; 50 is the peer median.

Growth60
Risk55
Performance45
Valuation62
Profitability57
Leverage43
Sentiment78
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$297.2M+11.6%
Net income-$51.6M
Net margin-17.4%+1.6 pts
Historical fundamentals

Revenue exposure

Regions, segments, customers and suppliers

Valuation

EOLSIndustryP/E—35.25P/S1.382.74EV/EBITDA—16.35P/B—2.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report
EPS estimate$-0.07
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate